Novel siRNA Produces Deep, Durable Reduction in Lp(a) in Phase 1 Trial

A Phase 1 trial of a novel long-duration small interfering RNA (siRNA) known as Kylo-11 demonstrated profound and extremely durable reductions in serum lipoprotein(a) (Lp(a)) levels. A single 600-mg dose resulted in a 97% median reduction from baseline at 48 weeks. The study, published in The Lancet and presented at the European Society of Cardiology Congress 2026, indicated that the drug was well tolerated with mostly mild to moderate adverse events.